Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Accurate detection of BCR-ABL fusion transcripts at and below molecular response (MR) 4 (0.01% International Scale [IS]) is required for disease monitoring in patients with chronic myeloid leukemia (CML). We evaluated the analytical performance of the QXDx BCR-ABL %IS (Bio-Rad, Hercules, CA, USA) droplet digital PCR (ddPCR) assay, which is the first commercially available ddPCR-based in vitro diagnostics product. In precision analysis, the %CV was 9.3% and 3.0%, with mean values of 0.031% IS and 9.4% IS, respectively. The assay was linear in the first order, ranging from 0.032% IS to 20% IS. The manufacturer-claimed limit of blank, limit of detection, and limit of quantification were verified successfully. There was a very strong correlation between the results of the QXDx BCR-ABL %IS ddPCR assay and the ipsogen BCR-ABL1 Mbcr IS-MMR (Qiagen, Hilden, Germany) real-time quantitative PCR assay (r=0.996). In conclusion, the QXDx BCR-ABL %IS ddPCR assay can provide reliable results for CML patients.
Abstract
Accurate detection of BCR-ABL fusion transcripts at and below molecular response (MR) 4 (0.01% International Scale [IS]) is required for disease monitoring in patients with chronic myeloid leukemia (CML). We evaluated the analytical performance of the QXDx BCR-ABL %IS (Bio-Rad, Hercules, CA, USA) droplet digital PCR (ddPCR) assay, which is the first commercially available ddPCR-based in vitro diagnostics product. In precision analysis, the %CV was 9.3% and 3.0%, with mean values of 0.031% IS and 9.4% IS, respectively. The assay was linear in the first order, ranging from 0.032% IS to 20% IS. The manufacturer-claimed limit of blank, limit of detection, and limit of quantification were verified successfully. There was a very strong correlation between the results of the QXDx BCR-ABL %IS ddPCR assay and the ipsogen BCR-ABL1 Mbcr IS-MMR (Qiagen, Hilden, Germany) real-time quantitative PCR assay (r=0.996). In conclusion, the QXDx BCR-ABL %IS ddPCR assay can provide reliable results for CML patients.
참고문헌 (18)
- Baccarani M, "A review of the European LeukemiaNet recommendations for the management of CML", Ann Hematol, 94, pp.S141~S147 (2015)
- Radich JP, "Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 16, pp.1108~1135 (2018)
- Branford S, "Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia", Leukemia, 20, pp.1925~1930 (2006)
- Jennings LJ, "Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR", J Mol Diagn, 16, pp.174~179 (2014)
- Kong JH, "Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?", Cancer, 123, pp.2482~2488 (2017)
- Cross NC, "Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia", Leukemia, 29, pp.999~1003 (2015)
- Alikian M, "RT-qPCR and RT-digital PCR : a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia", Clin Chem, 63, pp.525~531 (2017)
- Wang WJ, "Droplet digital PCR for BCR", ABL (P210) detection of chronic myeloid leukemia: a high sensitive method of the minimal residual disease and disease progression, 2018, pp.101, 291~296
- Maier J, "Optimized digital droplet PCR for BCR-ABL", J Mol Diagn, 21, pp.27~37 (2019)
- "QXDx BCR-ABL %IS Kit. Instructions for use"[URL]
- "QIAGEN ipsogen BCR-ABL1 Mbcr IS-MMR DX Kit Handbook"[URL]
- Gabert J, "Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia–a Europe against cancer program", Leukemia, 17, pp.2318~2357 (2003)
- Beillard E, "Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)–a Europe against cancer program", Leukemia, 17, pp.2474~2486 (2003)
- CLSI, "User verification of precision and estimation of bias; approved guideline" (2014), Clinical and Laboratory Standards Institute
- CLSI, "Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline" (2003), Clinical and Laboratory Standards Institute
- CLSI, "Evaluation of detection capability for clinical laboratory measurement procedures; approved guideline" (2012), Clinical and Laboratory Standards Institute
- CLSI, "Measurement procedure comparison and bias estimation using patients; approved guideline" (2013), Clinical and Laboratory Standards Institute
- Huggett JF, "Considerations for digital PCR as an accurate molecular diagnostic tool", Clin Chem, 61, pp.79~88 (2015)